A man can leave a 30-day rehab, swear he has turned a corner, and still be back on the same corner before the month is out. The family that paid for the bed, borrowed the money, and rearranged their lives for the discharge date gets a hard lesson: treatment can look decisive from the outside while the addiction itself has barely shifted.
This is the fight running through addiction care here. One side wants firmer control, stricter abstinence, tougher rules, even compulsory treatment for people who keep collapsing into the same damage. The other side says punishment dressed as care has already failed too many families; the real answer is lower barriers, safer use, better medicine, and treatment that keeps people alive long enough to change.
The fight is really about control
The loudest argument in addiction treatment is not about one drug or one clinic. It is about who gets to decide when a person has crossed the line from choice into incapacity.
Those pushing involuntary treatment argue that severe addiction can crush judgement. They point to a person who keeps using despite lost jobs, broken relationships, arrests, and hospital visits, then say the brain circuits tied to reward and impulse have been hijacked. On that reading, waiting for someone to ask for help can mean waiting until they are dead.
Critics do not buy the leap from desperation to coercion. They point to poor long-term outcomes from forced care, the abuse that often follows when a person has no exit, and the overdose danger that rises after release because tolerance has dropped. A person can be locked up, dried out, and discharged without any real plan, then go straight back to using with less protection than before.
This split shapes what kind of beds get funded, which programmes get praised, and whether relapse is treated as a clinical setback or a moral failure. It also decides whether treatment is built around consent and continuity, or around containment and discipline.
Harm reduction gets accused of helping people use
Needle exchange programmes draw the same kind of anger, only louder. In communities hit by nyaope and heroin, some people see clean needles and think the system has given up on stopping drug use. They hear “harm reduction” as a polite phrase for surrender.
This is the wrong reading. Needle exchange exists because dirty injecting equipment spreads HIV and hepatitis C with brutal efficiency. South Africa already carries one of the world’s largest HIV burdens, with about 7.9 million people living with HIV in 2022. Sharing a syringe is one of the fastest ways to turn drug use into a lifelong medical crisis.
The strongest case for needle exchange is practical, not sentimental. It reduces infections, gives staff a point of contact, and lets services hand over counselling, referrals, wound care, and basic education before a user disappears again. Groups such as TB/HIV Care and Médecins Sans Frontières have used these kinds of programmes in places like Durban and Pretoria, usually as part of broader health outreach rather than as a stand-alone gesture.
The objection is equally blunt. Critics say clean needles normalise use, attract crime, and offer no exit. This criticism has political force because people can see the discarded equipment, the street dealing, and the public mess. They cannot as easily see the infections that never happen, the abscesses that do not become amputations, and the users who finally walk into care because the first contact was not judgment.
Nyaope makes the argument harder to dodge. It is not a neat, single-substance problem. Users often describe a mixture that can include heroin, antiretrovirals, rat poison, and other ingredients. This kind of drug supply raises the risk of infection, overdose, and unpredictable withdrawal. Pretending every user should simply stop on command is a good way to keep people dying while the argument stays pure.
The rehab market has filled the gaps with dangerous shortcuts
If you want to see how broken the system is, look at the growth of unregistered rehabs. They appear where state beds are full, private treatment is out of reach, and families are desperate enough to accept almost anything that sounds like structure.
Private rehab can cost R20,000 to R100,000 or more a month. For most households, that is fantasy. State-funded beds can involve waits of three to six months. By the time a placement comes through, the crisis has often moved on, a parent has given up, or the person needing help has already been through several more rounds of damage.
This vacuum created a market for backyard rehabs, often run from houses, halls, or improvised premises with little oversight. Some are started by former users or community leaders who want to do good and do not know enough. Others are harsher than that, with no qualified medical staff, no psychiatric care, and no real plan for withdrawal beyond control.
The worst versions cross into abuse. People have reported restraint, isolation, forced labour, punishment, starvation, and denial of medication. Without registration under the Department of Social Development, there is no proper inspection regime, no standard of care to enforce, and often no one to answer when a client is harmed.
The defenders of these places make a fairer point than their critics like to admit. They are open now. They are cheap or free. They can feel more accessible than a formal system that talks about dignity while keeping people on a waiting list. But accessibility alone is not treatment. A place can be near, available, and disastrous.
Abstinence can work, but it cannot be the whole plan
South African addiction care still leans hard on strict abstinence. In some communities that is wrapped in faith language, in others in discipline and rules. The appeal is obvious. People want a clear line: stop using, cut ties, start over.
Faith-based programmes can offer real support. They are often affordable, sometimes free, and many people find belonging in them when formal services feel cold or impossible to reach. Prayer, routine, and fellowship can steady someone who has lived in chaos for years.
The problem starts when spiritual change is treated as a substitute for medicine. Addiction rarely arrives alone. Trauma, depression, anxiety, psychosis, and unstable housing are common parts of the picture. If a programme only offers repentance and rules, it may produce short-term compliance without touching the psychiatric damage underneath.
This gap matters most for opioid dependence. Opioid Substitution Therapy, usually with methadone or buprenorphine, can reduce withdrawal, lower overdose risk, and keep people engaged in treatment. Some faith-based centres reject it as replacing one drug with another. That slogan sounds firm, but it keeps people cycling through relapse, infection, and criminalisation while the place congratulates itself on purity.
Evidence-based care does not ask for spiritual contempt. It asks for medical honesty. If someone needs therapy, medication, trauma work, and a community that stops them from disappearing, that is not weakness. It is a proper treatment plan.
Cannabis is still a legal trap for adolescents
Cannabis decriminalisation has added another layer of confusion. Adults can cultivate and possess it for private use after the 2018 Constitutional Court ruling in Prince v Minister of Justice and Constitutional Development. That does not make it harmless. It does not legalise commercial sale. It does not give minors a free pass.
The problem is perception. Some adolescents hear “decriminalised” and translate it as “safe”. Clinicians are dealing with the fallout from that misunderstanding, especially where frequent use overlaps with school problems, low motivation, anxiety, and psychosis.
The mental health concern is not imaginary. Regular cannabis use during adolescence can interfere with memory, attention, and problem-solving at a stage when the brain is still developing. In vulnerable young people, it can also contribute to cannabis-induced psychosis and, in some cases, broader psychotic illness.
The honest position here is not panic and not permissiveness. Decriminalisation for adults did not solve youth risk, and did not remove the need for prevention, early screening, and family intervention. A teenager who is already struggling does not become less at risk because the law softened for grown adults.
The next wave of treatment is promising, but access will decide everything
A lot of the new talk in addiction medicine sounds futuristic until you remember who gets to use it. GLP-1 drugs such as semaglutide, sold as Ozempic, are being explored for alcohol and substance cravings because they seem to influence reward pathways in the brain. This is interesting, but it is also expensive, not standard addiction care, and not something most people will touch unless the evidence and access both improve.
Psychedelic-assisted treatment is moving in a different direction. Psilocybin and MDMA are being studied for trauma and severe substance use disorders, especially where post-traumatic stress sits underneath the addiction. The promise is real enough, but any local rollout would need regulatory approval, trained clinicians, and ethics oversight that can handle the risks properly.
New medicines for synthetic opioid and stimulant withdrawal are also part of the conversation. They could help with some of the ugliest detox cases, especially where users are dealing with strong street drugs and unstable health. The catch is the usual one: a drug is only useful if someone can prescribe it, stock it, and monitor it.
The same applies to digital tools. Smartphone apps, telehealth, and AI monitoring can widen access, especially outside major cities. They may help people who cannot travel often, or who need follow-up between visits. But a low-cost app does nothing for someone without data, a phone that works, or the privacy to use it safely at home.
Dual diagnosis is where many programmes still fail
A lot of addiction care still treats substance use as the only problem in the room. That is how people get discharged “clean” and remain clinically unwell.
Trauma, depression, and anxiety are not side notes. They are often part of the engine driving the substance use in the first place. If a programme detoxes the body but ignores the mind, the person walks out with the same pain and fewer coping tools. Relapse then gets blamed on weakness instead of being recognised as the predictable result of unfinished treatment.
This is where the divide between faith-based and evidence-based care becomes more than ideology. If a centre does not have psychiatric screening, medication support, and staff who can handle dual diagnosis, it is not equipped for a huge share of real-world cases. It may still provide comfort. It may still save some people. But it will also miss the ones whose addiction is tied to panic, abuse, insomnia, paranoia, or untreated depression.
South Africa’s unequal system makes this worse. The people most in need of integrated care are often the least able to buy it. That leaves families choosing between expensive private treatment, overstretched public services, and informal centres that may be compassionate, abusive, or both.
The hard questions families should ask
Before paying for a bed or agreeing to a placement, ask direct questions.
Does the programme have medical staff who can manage withdrawal safely? Does it screen for trauma, depression, anxiety, and psychosis? Does it offer opioid substitution therapy or a clear referral pathway for it? Is it registered, and who inspects it? What happens if the person relapses after discharge? What support exists after the stay ends?
Those questions will not make the system fair. They will make it harder to hide nonsense behind moral language.
Recovery here is not choosing between a saintly abstinence model and a reckless permissive one. It is choosing the least damaging path for a real person in a real situation, then building enough follow-up so the first decision does not become the last one.
